Cite
Caminati M, Batani V, Guidolin L, et al. One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response. Eur J Intern Med. 2022;doi: 10.1016/j.ejim.2021.12.026.
Caminati, M., Batani, V., Guidolin, L., Festi, G., & Senna, G. (2022). One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response. European journal of internal medicine, . https://doi.org/10.1016/j.ejim.2021.12.026
Caminati, Marco, et al. "One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response." European journal of internal medicine vol. (2022). doi: https://doi.org/10.1016/j.ejim.2021.12.026
Caminati M, Batani V, Guidolin L, Festi G, Senna G. One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response. Eur J Intern Med. 2022 Jan 06; doi: 10.1016/j.ejim.2021.12.026. Epub 2022 Jan 06. PMID: 34998664.
Copy
Download .nbib